NEPH (Nephros) Loans Receivable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Nephros Loans Receivable?

Nephros's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Nephros Loans Receivable Historical Data

The historical data trend for Nephros's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nephros Loans Receivable Chart

Nephros Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

Nephros Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Nephros Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Nephros Loans Receivable Related Terms

Thank you for viewing the detailed overview of Nephros's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nephros Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nephros Inc (NAS:NEPH) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

NPJP:Germany

Address

380 Lackawanna Place, South Orange, NJ, USA, 07079

Website

https://www.nephros.com

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Executives

Arthur H Amron	director	C/O WEXFORD CAPITAL LP, 777 WEST PUTNAM AVENUE, FIRST FLOOR, GREENWICH CT 06830
Banks Robert R. Jr.	director, officer: President and CEO	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Judy Krandel	officer: Chief Financial Officer	320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018
Joseph Michael Harris	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Wesley S. Lobo	officer: Chief Marketing Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Tom Gwydir	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Andrew Astor	officer: Chief Financial Officer	380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Charles E Davidson	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	director, 10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Gp Llc	director, 10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Oliver J. Spandow	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daniel S. D'agostino	officer: Chief Financial Officer	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Daron Evans	director, officer: President and CEO	C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079